Director: Heather Johnson, PharmD
The PGY1 pharmacy residency at UPMC Presbyterian Shadyside offers the resident with a variety of learning experiences within the UPMC Health System. Residents will gain clinical experience diverse practices settings as well as serve on multidisciplinary hospital committees, develop an implement drug-use initiatives, participate in journal clubs, and present seminars. Through the Resident Research Series, residents identify a practice-related research project and mentor, learn about study design and implementation as well as complete a residency project suitable for publication. The Teaching Mastery Series allows residents to learn about various teaching methods as well as develop their skills as pharmacy educators and clinical preceptors. Flexibility is provided to meet the individual resident's goals and objectives.
Program objectives include: (1) demonstrate proficiency, confidence, and compassion in providing direct patient care to diverse populations; (2) demonstrate professionalism and effective communication skills in all components of pharmacy practice; (3) optimize pharmacotherapy and safe medication practices; (4) provide effective education to healthcare professionals; and (5) apply clinical and outcomes research concepts to professional practice.
Residents come to the University of Pittsburgh School of Pharmacy programs from far and wide, representing more than 25 US States and foreign countries. All residents must be eligible for pharmacist licensure in the Commonwealth of Pennsylvania. Applications for Pharmacist License and Intern Registration are available.
Pennsylvania requires 1500 registered intern hours in order to be eligible for licensure. Of the 1500 hours, only 750 hours can be obtained through an academic program. That is, 750 intern hours must be obtained outside of school. These 750 intern hours must be registered with a state board of pharmacy to count toward licensure in Pennsylvania. If you have not yet started registering hours with your state board of pharmacy, we encourage you to do so as soon as possible in order to be eligible for Pennsylvania licensure. We also encourage you to review your own state's rules regarding the registration, reporting and transfer of intern hours. Please do not hesitate to discuss any questions you have regarding licensure with individual program directors.
Eligible candidates will have a Doctor of Pharmacy degree from an ACPE-accredited school or college of pharmacy and must submit the standard application requirements via PhORCAS by December 31st. An on-site interview is required.
For more information contact Heather Johnson, PharmD, BCPS
To prepare pharmacists to assume any of the following roles:
• patient care provider
• PGY2 training in their specialty area of choice
• pharmacy educator
Our residents will become confident, effective practitioners of pharmacotherapy. Residents will focus on ensuring application of safe, effective and evidence-based medicine practices to individual patients and in populations across the health system. These practitioners will demonstrate competency in educating their patients as well as present and future health care professionals.
Schonder KS. Corman SL. Hung WY. Early risk factors for persistent anemia after kidney transplantation. Pharmacotherapy 30(12):1214-20, 2010 Dec.
Smithburger PL. Seybert AL. Armahizer MJ. Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medicatiosn and the impact of drug-drug interactions. [Review] Expert Opinion on Drug Safety. 9(5):699-712, 2010 Sep.
Lavsa SM. Fabian TJ. Saul MI. Corman SL. Coley KC. Influence of medicatiosn and diagnoses on fall risk in psychiatric inpatients. American Journal of Health-System Pharmacy. 67(15):1274-80, 2010 Aug.
Martello JL. Pummer TL. Krenzelok EP. Cost minimization analysis comparing enteral N-acetylcysteine to intravenous acetylcysteine in the management of acute acetaminophen toxicity. Clinical Toxicology: The Official Journal of the American Academy of Clinical Toxicology & European Association of Poisons Centres & Clinical Toxicologists. 48(1):79-83, 2010 Jan.
Shields RK. Martello JL. Potoski BA. Is vancomycin ototoxicity a significant risk? Antimicrobial Agents & Chemotherapy. 53(10):4572, 2009. Oct.
Havrilla PL. Kane-Gill SL. Verrico MM. Seybert AL. Reis SE. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Annals of Pharmacotherapy. 43(3):532-6, 2009 Mar.
Pogue JM. Paterson DL. Pasculle AW. Potoski BA Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infection Control & Hospital Epidemiology. 28(12):1382-8, 2007 Dec.